Indiana University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).
Indiana University: 890 sponsored US clinical trials, 156 recruiting.
Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.
Top-decile sponsor footprint
Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
890 total, page 12 of 18
MRSA Eradication and Decolonization in Children
NCT02127658
Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development
NCT02639676
Infant Night Wakings in Pediatric Primary Care
NCT02780596
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
NCT02697617
Use of ACTIMMUNE in Patients With ADO2
NCT02584608
Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease
NCT02739750
High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT)
NCT02592135
Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
NCT02611544
Finding the Patient's Voice Diabetes Prevention Programs
NCT02700503
Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia
NCT02580422
Gabapentin as Adjunctive Treatment for Postoperative Pain Control
NCT02490345
Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women
NCT04045652
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
NCT02408315
Pulmonary Compliance Changes During Manipulation of Early Onset Scoliosis and Cast Application
NCT02558985
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
NCT02549534
Biorepository for Precision Genomics
NCT02587026
miR-200b & miR-21 in Diabetic Wounds
NCT02581098
eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
NCT02458690
Information With or Without Numbers For Optimizing Reasoning About Medical Decisions
NCT02477553
Standardized Versus Tailored Implementation of Measurement Based Care for Depression
NCT02266134
Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
NCT02413047
DFMO in Children With Type 1 Diabetes
NCT02384889
Depression Therapy to Improve Cardiovascular Risk in HIV
NCT02309372
A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program
NCT02297126
PROMIS Measures in Primary Care Practice
NCT02383862
Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage
NCT02343263
Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia
NCT02466659
A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy
NCT02345889
Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery
NCT02436265
Cognitive and Aerobic Resilience for the Brain
NCT02390453
Modulation Of Airway Reactivity With Chronic Mechanical Strain
NCT02396849
King Vision Video Laryngoscope Ambu (aBlade) System for Use in Children
NCT02841189
Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury
NCT02240589
Antibiotic Irrigation for Pancreatoduodenectomy
NCT02186457
Iron Supplement to Improve Iron Status Following Bariatric Surgery
NCT02404012
Comparison of INFIX and Plating for Pelvic Ring Injuries With Symphysis Disruptions
NCT02399319
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses
NCT02248389
Improving Adolescent Health Outcomes Through Preventive Care Transformation
NCT02244138
Placental Transfusion Project for Preterm Infants
NCT02400697
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.
NCT02233322
Endoscopic Management of Esophageal Wall Defects
NCT04571541
A Phase II Study of Neoadjuvant FOLFIRINOX
NCT02178709
Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions
NCT02172664
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
NCT02103855
Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy
NCT02131376
Lifestyle-Related Health Outcomes in Prediabetes and Diabetes
NCT02535169
Integrated Metacognitive Therapy in First Episode Psychosis
NCT02131116
Advancing Diabetes Management in Adolescents Using Health Information Technology
NCT02115555
Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery
NCT02724033
rTMS in First Episode Psychosis
NCT02131129
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 70 |
| Phase 3 | 28 |
| Phase 4 | 76 |
Therapeutic Areas
What is open in the Indiana University pipeline
156 recruiting of 890 indexed (18% open); 561 completed (63%).
Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).
Top condition: Alzheimer Disease (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Indiana University: open-pipeline peers nationwide
Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 890 trials (± recruiting share)
- University of California, Los Angeles · 897 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Edwards Lifesciences · 18% recruiting · 57 trials
- University of South Florida · 17% recruiting · 252 trials
- VA Office of Research and Development · 17% recruiting · 1,668 trials
- ConvaTec · 18% recruiting · 17 trials
Related
What to do with this Indiana University page
890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.
- 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.